Wells Fargo Upgrades Travere Therapeutics to Overweight From Equalweight, Adjusts Price Target to $27 From $9
Wells Fargo Upgrades Travere Therapeutics to Overweight From Equalweight, Adjusts Price Target to $27 From $9
富國銀行將Travere Therapeutics的評級從等權升級爲超重,將目標股價從9美元調整爲27美元
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊